In the developed world, cancer will affect one in three people at some stage in their life. Many of us have already been touched by the disease, in one way or another. However, you would be wrong to think that progress is not being made.
Without research we are condemning tomorrow's generation to today's treatments. That is why it is vitally important that AICR's funding of cutting edge projects continues - so that new treatments can be developed for the next generation. Here are some of the success stories our donors' money has funded:
Herbal Medicine Warning in Asia
Scientists from King’s College London are warning that millions of people may be exposed to risk of developing kidney failure and bladder cancer by taking herbal medicines that are widely available in Asia.
The medicines, used for a wide range of conditions including slimming, asthma and arthritis, are derived from a botanical compound containing aristolochic acids. These products are now banned in the USA and many European countries but the herbs containing this toxic acid can still be bought in China and other countries in Asia and are also available worldwide over the internet. More>>
MRC Technology, a technology transfer charity and company, has reported successful results from the first year of its agreement with the Association for International Cancer Research (AICR). The partnership enables AICR to take advantage of MRC Technology’s IP management, technology transfer, and drug discovery expertise, to help maximise the health benefits and revenue derived from AICR-funded research.
Over the year, MRC Technology’s experts reviewed and monitored 25 priority projects from AICR’s overall portfolio, advising on development and commercialisation as appropriate. More>>
Taking omega-3 fish oils could help to protect against skin cancer, according to researchers at The University of Manchester. The team has just carried out the first clinical trial to examine the impact of the fish oils on the skin immunity of volunteers. Led by Professor Lesley Rhodes, Professor of Experimental Dermatology from the Photobiology Unit Dermatology Centre at the University, the study analysed the effect of taking omega-3 on 79 healthy volunteers. More>>
Stopping the growth and spread of pancreatic cancer is the focus of a new project led by researchers at the University of Hertfordshire and funded by the Association for International Cancer Research.
Pancreatic cancer is the tenth most common cancer in the UK, around 8,500 people were diagnosed in 2010. It is an aggressive cancer that very few people survive from – only around four per cent of pancreatic cancer patients survive for five years or more, making it one of the lowest survival rates. It is often diagnosed at an advanced stage when the cancer has become very aggressive and it quickly spreads to other organs of the body. Currently there is no effective treatment for the disease at this advanced stage. More>>
Scientists working at the Peter MaCallum Cancer Centre (Peter Mac) in Melbourne, Australia have discovered a possible cause why the most common type of ovarian cancer often becomes resistant to chemotherapy. The findings were published in the journal Cancer Research*.
Ovarian cancer kills more than 4000 women in the UK every year. High Grade Serous Cancer is the most common type of ovarian cancer, and accounts for around 65% of these deaths. Chemotherapy for the HGSC type of ovarian cancer can be very effective to begin with, but too often these tumours stop responding to chemotherapy over time.
With a grant from AICR, Dr Prue Cowell and Dr David Bowtell have identified a gene that appears to play an important role in HGSC tumours becoming resistant to treatment. More>>